West Pharmaceutical Services (WST) Net Cash Flow (2009 - 2026)

West Pharmaceutical Services (WST) has reported Net Cash Flow for 18 consecutive years, with -$84.0 million the latest figure, recorded in Q2 2026.

• Quarterly Net Cash Flow fell 196.55% year-over-year to -$84.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$59.8 million (down 224.32% YoY) and the FY2025 annual result came in at $283.8 million, up 181.58% from the prior year.
• Net Cash Flow grew to -$84.0 million in Q2 2026 per WST's latest filing, from -$261.5 million in the prior quarter.
• Over the last five years, Net Cash Flow for WST reached as high as $163.3 million in Q4 2025 and fell as low as -$261.5 million in Q1 2026.
• A 5-year average of -$17.7 million and a median of $700000.0 in 2023 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2024 — Net Cash Flow sank 1522.67% — and 2025, when it jumped 895.73%.
• Year by year, Net Cash Flow stood at $126.5 million in 2022, then slumped by 146.8% to -$59.2 million in 2023, then surged by 127.7% to $16.4 million in 2024, then soared by 895.73% to $163.3 million in 2025, then plunged by 151.44% to -$84.0 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$84.0 million, -$261.5 million, and $163.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.